RSS 1.0Haematology (Scholarly Publications)
Recent Submissions
-
Low CD49d expression in newly diagnosed chronic lymphocytic leukaemia may be associated with high-risk features and reduced treatment-free-intervals
(2022)This study was carried out to assess the prognostic power of low CD49d expres- sion (≥10%) in newly diagnosed CLL patients using a previously described cohort. Eighty-five patients were included. Median age at diagnosis; ... -
A novel aryl-guanidinium derivative, VP79s, targets the signal transducer and activator of transcription 3 signaling pathway, downregulates myeloid cell leukaemia-1 and exhibits preclinical activity against multiple myeloma
(2022)Aims: We have recently described a novel guanidinium-based compound, VP79s, which induces cytotoxicity in various cancer cell lines. Here, we aim to investigate the activity of VP79s and associated mechanisms of action in ... -
Epidemiology of chronic lymphocytic leukaemia in an Irish subpopulation with total case ascertainment: an additional tool for health economic planning
(2021)Chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) is the commonest B-cell malignancy affecting Caucasians, with a variable national incidence depending on the ethnic composition and age profile of ... -
The Impact of Advanced Patient Age on Mortality after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: A Retrospective Study by the European Society for Blood and Marrow Transplantation Lymphoma Working Party
(2019)More than 60% of patients with non-Hodgkin lymphoma (NHL) are age>60 years at presentation. The purpose of thisstudy was to compare the potential risks and benefits of allogeneic hematopoietic cell transplantation (alloHCT) ... -
Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents
(2018)The advent of novel agents for multiple myeloma (MM) is cause for a re-examination of the incidence of second primary malignancies (SPMs). We examined the SPM rate in MM patients who were enrolled in the prospective ... -
Melphalan 140 mg/m2or 200 mg/m2for autologous transplantation in myeloma: Results from the collaboration to collect autologous transplant outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT chronic malignancies working party
(2018)Melphalan at a dose of 200 mg/m2 is standard conditioning prior to autologous hematopoietic stem cell transplantation for multiple myeloma, but a dose of 140 mg/m2 is often used in clinical practice in patients perceived ... -
MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1.
(2013)Neuroblastoma is responsible for 15% of all childhood cancer deaths. Despite advances in treatment and disease management, the overall 5-year survival rates remain poor in high-risk disease (25-40%). MiR-497 was previously ... -
The microtubule targeting agent PBOX-15 inhibits integrin-mediated cell adhesion and induces apoptosis in acute lymphoblastic leukaemia cells
(2013)Although recent decades have seen an improved cure rate for newly diagnosed paediatric acute lymphoplastic leukemia (ALL), the treatment options for adult ALL, T-cell ALL (T-ALL) and relapsed disease remain poor. We have ... -
Quantification of unfractionated heparin in human plasma and whole blood by means of novel fluorogenic anti-FXa assays
(Elsevier, 2011)Novel and sensitive plate-based fluorogenic anti-factor Xa (FXa) assays were investigated to quantify unfractionated heparin (UFH) in human plasma and whole blood within the therapeutic ranges of 0-1.6 U/mL and 0?0.8 U/mL, ... -
Multifunctional specificity of the protein C/activated protein C Gla domain.
(American Society for Biochemistry and Molecular Biology, 2006)Activated protein C (APC) has potent anticoagulant and anti-inflammatory properties that are mediated in part by its interactions with its cofactor protein S and the endothelial cell protein C receptor (EPCR). The protein ... -
ADAMTS13 substrate recognition of von Willebrand factor A2 domain.
(2006)ADAMTS13 controls the multimeric size of circulating von Willebrand factor (VWF) by cleaving the Tyr1605?Met1606 bond in theA2 domain. To examine substrate recognition, we expressed in bacteria and purified three A2 ... -
Dissociation of activated protein C functions by elimination of protein S cofactor enhancement.
(2008)Activated protein C (APC) plays a critical anticoagulant role in vivo by inactivating procoagulant factor Va and factor VIIIa and thus down-regulating thrombin generation. In addition, APC bound to the endothelial cell ... -
Platelet factor 4 impairs the anticoagulant activity of activated protein C.
(2009)Platelet factor 4 (PF4) is an abundant platelet -granule chemokine released following platelet activation. PF4 interacts with thrombomodulin and the -carboxyglutamic acid (Gla) domain of protein C, thereby enhancing ... -
Severe Plasmodium falciparum malaria is associated with circulating ultra-large von Willebrand multimers and ADAMTS13 inhibition.
(2009)Plasmodium falciparum infection results in adhesion of infected erythrocytes to blood vessel endothelium, and acute endothelial cell activation, together with sequestration of platelets and leucocytes. We have previously ... -
A new microtubule-targeting compound PBOX-15 inhibits T-cell migration via post-translational modifications of tubulin.
(2008)The ordered, directional migration of T-lymphocytes is a key process during immune surveillance, immune response, and development. A novel series of pyrrolo-1,5-benzoxazepines have been shown to potently induce apoptosis ...
